Nasus Pharma shareholders approve all but one item

Nasus Pharma Ltd. reported that shareholders at its October 8, 2026 Annual and Special General Meeting approved all agenda items except Proposal No. 4, by the applicable required majority.

Rhea-AI Filing Summary

Nasus Pharma Ltd. reported that shareholders at its October 8, 2026 Annual and Special General Meeting approved all agenda items except Proposal No. 4, by the applicable required majority. A quorum was present. The report is incorporated by reference into the company’s Form F-3 and Form S-8 registration statements, subject to later-filed or furnished documents or reports.

Key Terms

quorum, applicable required majority, incorporated by reference

3 terms

quorum regulatory

"a quorum was present"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

applicable required majority regulatory

"approved, by the applicable required majority"

incorporated by reference regulatory

"is incorporated by reference into the Company’s Registration Statements"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NSRX shareholders approve at the October 8, 2026 meeting?

NSRX shareholders approved all agenda items except Proposal No. 4 by the applicable required majority. A quorum was present.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/08/2026 - 04:30 PM Accepted by SEC EDGAR 10/08/2026 - 04:30 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-42796

Nasus Pharma Ltd.

P.O. Box 284

Tel Aviv, Israel 6100201

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Results of Annual and Special General Meeting of Shareholders

On October 8, 2026, Nasus Pharma Ltd. (the “Company”) convened an Annual and Special General Meeting of Shareholders (the “Meeting”).

At the Meeting, a quorum was present and the shareholders of the Company voted upon and approved, by the applicable required majority, all agenda items except for Proposal No. 4 as described in the Company’s notice for the Meeting and proxy statement for the Meeting, which were included as Exhibits 99.1 and 99.2, respectively, to the Company’s Report of Foreign Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission on September 4, 2026.

Incorporation By Reference

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-298693) and Form S-8 (File No. 333-296252), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NASUS PHARMA LTD.
Date: October 8, 2026	By:	/s/ Brendan O’Grady
	Name:	Brendan O’Grady
	Title:	Chief Executive Officer